Macrophages and the Maintenance of Homeostasis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Immuno-Oncology Panel 1
Immuno-Oncology panel 1 Gene Symbol Target protein name UniProt ID (& link) Modification* (56 analytes) ADA17 ADAM17 metalloprotease domain 17 P78536 *blanks mean the assay detects the ANXA1 Annexin A1 P04083 non-modified peptide sequence ANXA1 Annexin A1 P04083 ARG2 arginase, type II P78540 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS2996 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS367 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 C10orf54 / VISTA chromosome 10 open reading frame 54 Q9H7M9 CCL5 C-C motif chemokine ligand 5 P13501 CD14 CD14 molecule P08571 CD163 CD163 molecule Q86VB7 CD274 / PDL1 Programmed cell death 1 ligand 1 CD274 Q9NZQ7 CD33 CD33 molecule P20138 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD47 CD47 molecule Q08722 CD70 CD70 antigen P32970 CD74/HG2A CD74 molecule, major histocompatibility complex, class II invariant chain Q8SNA0 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 P31997 CX3CL1 C-X3-C motif chemokine ligand 1 P78423 CXCL10 C-X-C motif chemokine ligand 10 P02778 CXCL13 chemokine (C-X-C motif) ligand 13 O43927 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 Q86VV3 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 pY291 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 HAVCR2 hepatitis -
Energy Healing
57618_CH03_Pass2.QXD 10/30/08 1:19 PM Page 61 © Jones and Bartlett Publishers, LLC. NOT FOR SALE OR DISTRIBUTION. CHAPTER 3 Energy Healing Our remedies oft in ourselves do lie. —WILLIAM SHAKESPEARE LEARNING OBJECTIVES 1. Describe the types of energy. 2. Explain the universal energy field (UEF). 3. Explain the human energy field (HEF). 4. Describe the seven auric layers. 5. Describe the seven chakras. 6. Define the concept of energy healing. 7. Describe various types of energy healing. INTRODUCTION For centuries, traditional healers worldwide have practiced methods of energy healing, viewing the body as a complex energy system with energy flowing through or over its surface (Rakel, 2007). Until recently, the Western world largely ignored the Eastern interpretation of humans as energy beings. However, times have changed dramatically and an exciting and promising new branch of academic inquiry and clinical research is opening in the area of energy healing (Oschman, 2000; Trivieri & Anderson, 2002). Scientists and energy therapists around the world have made discoveries that will forever alter our picture of human energetics. The National Institutes of Health (NIH) is conducting research in areas such as energy healing and prayer, and major U.S. academic institutions are conducting large clinical trials in these areas. Approaches in exploring the concepts of life force and healing energy that previously appeared to compete or conflict have now been found to support each other. Conner and Koithan (2006) note 61 57618_CH03_Pass2.QXD 10/30/08 1:19 PM Page 62 © Jones and Bartlett Publishers, LLC. NOT FOR SALE OR DISTRIBUTION. 62 CHAPTER 3 • ENERGY HEALING that “with increased recognition and federal funding for energetic healing, there is a growing body of research that supports the use of energetic healing interventions with patients” (p. -
Purinergic Signalling in Skin
PURINERGIC SIGNALLING IN SKIN AINA VH GREIG MA FRCS Autonomic Neuroscience Institute Royal Free and University College School of Medicine Rowland Hill Street Hampstead London NW3 2PF in the Department of Anatomy and Developmental Biology University College London Gower Street London WCIE 6BT 2002 Thesis Submitted for the Degree of Doctor of Philosophy University of London ProQuest Number: U643205 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U643205 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 ABSTRACT Purinergic receptors, which bind ATP, are expressed on human cutaneous kératinocytes. Previous work in rat epidermis suggested functional roles of purinergic receptors in the regulation of proliferation, differentiation and apoptosis, for example P2X5 receptors were expressed on kératinocytes undergoing proliferation and differentiation, while P2X? receptors were associated with apoptosis. In this thesis, the aim was to investigate the expression of purinergic receptors in human normal and pathological skin, where the balance between these processes is changed. A study was made of the expression of purinergic receptor subtypes in human adult and fetal skin. -
Wound Classification
Wound Classification Presented by Dr. Karen Zulkowski, D.N.S., RN Montana State University Welcome! Thank you for joining this webinar about how to assess and measure a wound. 2 A Little About Myself… • Associate professor at Montana State University • Executive editor of the Journal of the World Council of Enterstomal Therapists (JWCET) and WCET International Ostomy Guidelines (2014) • Editorial board member of Ostomy Wound Management and Advances in Skin and Wound Care • Legal consultant • Former NPUAP board member 3 Today We Will Talk About • How to assess a wound • How to measure a wound Please make a note of your questions. Your Quality Improvement (QI) Specialists will follow up with you after this webinar to address them. 4 Assessing and Measuring Wounds • You completed a skin assessment and found a wound. • Now you need to determine what type of wound you found. • If it is a pressure ulcer, you need to determine the stage. 5 Assessing and Measuring Wounds This is important because— • Each type of wound has a different etiology. • Treatment may be very different. However— • Not all wounds are clear cut. • The cause may be multifactoral. 6 Types of Wounds • Vascular (arterial, venous, and mixed) • Neuropathic (diabetic) • Moisture-associated dermatitis • Skin tear • Pressure ulcer 7 Mixed Etiologies Many wounds have mixed etiologies. • There may be both venous and arterial insufficiency. • There may be diabetes and pressure characteristics. 8 Moisture-Associated Skin Damage • Also called perineal dermatitis, diaper rash, incontinence-associated dermatitis (often confused with pressure ulcers) • An inflammation of the skin in the perineal area, on and between the buttocks, into the skin folds, and down the inner thighs • Scaling of the skin with papule and vesicle formation: – These may open, with “weeping” of the skin, which exacerbates skin damage. -
Epigenetic Regulations of Ahr in the Aspect of Immunomodulation
International Journal of Molecular Sciences Review Epigenetic Regulations of AhR in the Aspect of Immunomodulation Anna Wajda 1,* , Joanna Łapczuk-Roma ´nska 2 and Agnieszka Paradowska-Gorycka 1 1 Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland; [email protected] 2 Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] * Correspondence: [email protected] Received: 31 July 2020; Accepted: 28 August 2020; Published: 3 September 2020 Abstract: Environmental factors contribute to autoimmune disease manifestation, and as regarded today, AhR has become an important factor in studies of immunomodulation. Besides immunological aspects, AhR also plays a role in pharmacological, toxicological and many other physiological processes such as adaptive metabolism. In recent years, epigenetic mechanisms have provided new insight into gene regulation and reveal a new contribution to autoimmune disease pathogenesis. DNA methylation, histone modifications, chromatin alterations, microRNA and consequently non-genetic changes in phenotypes connect with environmental factors. Increasing data reveals AhR cross-roads with the most significant in immunology pathways. Although study on epigenetic modulations in autoimmune diseases is still not well understood, therefore future research will help us understand their pathophysiology and help to find new therapeutic strategies. Present literature review -
Environmental Pollution 275 (2021) 116665
Environmental Pollution 275 (2021) 116665 Contents lists available at ScienceDirect Environmental Pollution journal homepage: www.elsevier.com/locate/envpol Metabolomics reveals the reproductive abnormality in female zebrafish exposed to environmentally relevant levels of climbazole* Ting Zou a, 1, Yan-Qiu Liang b, 1, Xiaoliang Liao a, Xiao-Fan Chen a, Tao Wang c, * Yuanyuan Song c, Zhi-Cheng Lin a, Zenghua Qi a, Zhi-Feng Chen a, d, , Zongwei Cai a, c a Guangdong Key Laboratory of Environmental Catalysis and Health Risk Control, School of Environmental Science and Engineering, Institute of Environmental Health and Pollution Control, Guangdong University of Technology, Guangzhou, 510006, China b Faculty of Chemistry and Environmental Science, Guangdong Ocean University, Zhanjiang, 524088, China c State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong Special Administrative Region, China d Guangdong Provincial Key Laboratory of Chemical Pollution and Environmental Safety, South China Normal University, Guangzhou, 510006, China article info abstract Article history: Climbazole (CBZ) ubiquitously detected in the aquatic environment may disrupt fish reproductive Received 15 November 2020 function. Thus far, the previous study has focused on its transcriptional impact of steroidogenesis-related Received in revised form genes on zebrafish, but the underlying toxic mechanism still needs further investigation at the metabolic 10 January 2021 level. In this study, adult zebrafish were chronically exposed to CBZ at concentrations of 0.1 (corre- Accepted 2 February 2021 sponding to the real concentration in surface water), 10, and 1000 mg/L and evaluated for reproductive Available online 5 February 2021 function by egg production, with subsequent ovarian tissue samples taken for histology, metabolomics, and other biochemical analysis. -
Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G. -
Lipoxin A4: a Novel Anti-Inflammatory Molecule? Thorax: First Published As 10.1136/Thx.50.2.111 on 1 February 1995
Thorax 1995;50:111-112 illl Lipoxin A4: a novel anti-inflammatory molecule? Thorax: first published as 10.1136/thx.50.2.111 on 1 February 1995. Downloaded from Arachidonic acid is metabolised by the cyclooxygenase contractions.22 These studies support the view that LXA4 pathway to the prostaglandins and thromboxane A2 or via may act as a partial agonist at the same or similar site as one of the lipoxygenase pathways.' Three major lip- the sulphidopeptide leukotrienes. oxygenase pathways have been identified in mammalian The fact that 1 5-lipoxygenase is abundant in lung tissue tissue - namely, the 5-, 12-, and 15-lipoxygenases.2A The and that LXA4 has been recovered in the bronchoalveolar 5-lipoxygenase pathway metabolises arachidonic acid lavage fluid ofpatients with asthma and other lung diseases through two intermediates, 5-hydroperoxyeicosatetranoic suggests that LXA4 may be a potential mediator or mod- acid (5-HPETE) and leukotriene A4 (LTA4), to LTB4 and ulator of inflammation in the lung. In a recent study eight the sulphidopeptide leukotrienes LTC4, LTD4, and LTE4.5 subjects underwent inhalation challenge with LXA4,23 but The sulphidopeptide leukotrienes are potent spasmogens6 no effect was seen on specific conductance, rate of airflow for non-vascular smooth muscle and may play a part in at 25% vital capacity (V25), blood pressure, pulse, or the pathogenesis of bronchial asthma.7`10 asthmatic symptoms. There was, however, a significant The interactions between 5-lipoxygenase and 15-lip- shift of the specific conductance and V25 dose-response oxygenase on arachidonic acid metabolism have recently curve to the right after inhalation challenge with LTC4 been studied and a new series of biologically active me- combined with LXA4 compared with that after inhalation tabolites described." 12 These molecules have been termed challenge with LTC4 alone. -
Wound Care: the Basics
Wound Care: The Basics Suzann Williams-Rosenthal, RN, MSN, WOC, GNP Norma Branham, RN, MSN, WOC, GNP University of Virginia May, 2010 What Type of Wound is it? How long has it been there? Acute-generally heal in a couple weeks, but can become chronic: Surgical Trauma Chronic -do not heal by normal repair process-takes weeks to months: Vascular-venous stasis, arterial ulcers Pressure ulcers Diabetic foot ulcers (neuropathic) Chronic Wounds Pressure Ulcer Staging Where is it? Where is it located? Use anatomical location-heel, ankle, sacrum, coccyx, etc. Measurements-in centimeters Length X Width X Depth • Length = greatest length (head to toe) • Width = greatest width (side to side) • Depth = measure by marking the depth with a Q- Tip and then hold to a ruler Wound Characteristics: Describe by percentage of each type of tissue: Granulation tissue: • red, cobblestone appearance (healing, filling in) Necrotic: • Slough-yellow, tan dead tissue (devitalized) • Eschar-black/brown necrotic tissue, can be hard or soft Evaluating additional tissue damage: Undermining Separation of tissue from the surface under the edge of the wound • Describe by clock face with patients head at 12 (“undermining is 1 cm from 12 to 4 o’clock”) Tunneling Channel that runs from the wound edge through to other tissue • “tunneling at 9 o’clock, measuring 3 cm long” Wound Drainage and Odor Exudate Fluid from wound • Document the amount, type and odor • Light, moderate, heavy • Drainage can be clear, sanguineous (bloody), serosanguineous (blood-tinged), -
SOCH111 History of Healing Last Modified: 17-Jun-2021
SUBJECT OUTLINE Subject Name: Subject Code: History of Healing SOCH111 SECTION 1 – GENERAL INFORMATION Award/s: Total Course Credit Points: Level: Bachelor of Health Science (Naturopathy) 128 1st Year Bachelor of Health Science (Myotherapy) 96 1st Year Bachelor of Health Science (Nutritional and Dietetic Medicine) 96 1st Year Bachelor of Complementary Medicine 48 1st Year Diploma of Health Science 32 1st Year Duration: 1 Semester Subject is: Core Subject Credit Points: 4 Student Workload: No. timetabled hours per week: No. personal study hours per week: Total hours per week: 6 4 10 Delivery Mode*: ☐ On campus ☒ Online / Digital ☐ Blended ☐ Intensive Weekly Session^ Format/s - 2 sessions per week: ☒ eLearning modules: Lectures: Interactive adaptive online learning modules Tutorials: can include asynchronous tutor moderated discussion forum and activities, learning journal activities or other web-based resources *All modes are supported by the online learning management system which will include subject documents such as handouts, readings and assessment guides. ^A ‘session’ is made up of 3 hours of timetabled / online study time per week unless otherwise specified. Each subject has a set number of sessions as outlined above. Study Pattern: ☒ Full Time ☒ Part Time Pre-requisites: Nil Co-requisites: Nil SECTION 2 – ACADEMIC DETAILS Subject Rationale This subject provides the student with an understanding of the history and philosophy underpinning traditional and other whole medical systems from early human existence to the present day in diverse cultures worldwide. Social, Australian College of Natural Medicine Pty Ltd trading as Endeavour College of Natural Health, FIAFitnation (National CRICOS #00231G, RTO #31489) SOCH111 History of Healing Last modified: 17-Jun-2021 Version: 27.0 Page 1 of 10 cultural and political developments are considered in the evolution of healing and medicine, as well as the parallel developments in anatomy, physiology and other sciences. -
Immune-Checkpoint Blockade Therapy in Lymphoma
International Journal of Molecular Sciences Review Immune-Checkpoint Blockade Therapy in Lymphoma Ayumi Kuzume 1,2, SungGi Chi 1 , Nobuhiko Yamauchi 1 and Yosuke Minami 1,* 1 Department of Hematology, National Cancer Center Hospital East, Kashiwa 277–8577, Japan; [email protected] (A.K.); [email protected] (S.C.); [email protected] (N.Y.) 2 Department of Hematology, Kameda Medical Center, Kamogawa 296–8602, Japan * Correspondence: [email protected]; Tel.: +81-4-7133-1111; Fax: +81-7133-6502 Received: 11 June 2020; Accepted: 28 July 2020; Published: 30 July 2020 Abstract: Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signaling, and reduce cytotoxicity and T-cell exhaustion. Immune-checkpoint blockade can inhibit this signal and may serve as an effective therapeutic strategy in patients with solid tumors. Several trials have been conducted on immune-checkpoint inhibitor therapy in patients with malignant lymphoma and their efficacy has been reported. For example, in Hodgkin lymphoma, immune-checkpoint blockade has resulted in response rates of 65% to 75%. However, in non-Hodgkin lymphoma, the response rate to immune-checkpoint blockade was lower. In this review, we evaluate the biology of immune-checkpoint inhibition and the current data on its efficacy in malignant lymphoma, and identify the cases in which the treatment was more effective. -
Targeting Costimulatory Molecules in Autoimmune Disease
Targeting costimulatory molecules in autoimmune disease Natalie M. Edner1, Gianluca Carlesso2, James S. Rush3 and Lucy S.K. Walker1 1Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF 2Early Oncology Discovery, Early Oncology R&D, AstraZeneca, Gaithersburg, MD, USA 3Autoimmunity, Transplantation and Inflammation Disease Area, Novartis Institutes for Biomedical Research, Basel, Switzerland *Correspondence: Professor Lucy S.K. Walker. Institute of Immunity & Transplantation, Division of Infection & Immunity, University College London, Royal Free Campus, London, UK NW3 2PF. Tel: +44 (0)20 7794 0500 ext 22468. Email: [email protected]. 1 Abstract Therapeutic targeting of immune checkpoints has garnered significant attention in the area of cancer immunotherapy, and efforts have focused in particular on the CD28 family members CTLA-4 and PD-1. In autoimmunity, these same pathways can be targeted to opposite effect, to curb the over- exuberant immune response. The CTLA-4 checkpoint serves as an exemplar, whereby CTLA-4 activity is blocked by antibodies in cancer immunotherapy and augmented by the provision of soluble CTLA-4 in autoimmunity. Here we review the targeting of costimulatory molecules in autoimmune disease, focusing in particular on the CD28 family and TNFR family members. We present the state-of-the-art in costimulatory blockade approaches, including rational combinations of immune inhibitory agents, and discuss the future opportunities and challenges in this field. 2 The risk of autoimmune disease is an inescapable consequence of the manner in which the adaptive immune system operates. To ensure effective immunity against a diverse array of unknown pathogens, antigen recognition systems based on random gene rearrangement and mutagenesis have evolved to anticipate the antigenic universe.